A Research Study on Etavopivat in Participants With and Without Liver Disease
Status:
COMPLETED
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.